Vivos Therapeutics Reports Q2 2025 Results With $3.8M Revenue, $4.9M Loss, Acquires Sleep Center of Nevada for OSA Treatment

Vivos Therapeutics reported its second quarter 2025 financial results, posting $3.8 million in revenue, $2.1 million in gross profit, and a $4.9 million operating loss. The company also completed the acquisition of the Sleep Center of Nevada to expand its obstructive sleep apnea (OSA) treatment offerings. OS Therapies released its Q2 2025 financial results and provided a business update, although specific financial details were not disclosed. Additionally, NuCana, Ascentage Pharma, Canadian North Resources Inc., Numinus Wellness Inc., Medicure, and Nutex Health announced their respective second quarter or interim financial results and business updates during the same period.